Acitretin
From Wikipedia, the free encyclopedia
 |
|
|
Acitretin
|
|
| Systematic (IUPAC) name | |
| 9-(4-methoxy-2,3, 6-trimethyl-phenyl)- 3,7-dimethyl-nona-2,4,6,8- tetraenoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | D05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H26O3 |
| Mol. mass | 326.429 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 49 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Acitretin (trade name Soriatane) is a second generation retinoid. It is taken orally, and is typically used for psoriasis.
It is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days.
Women must avoid becoming pregnant for at least 2 years after discontinuing acitretin. In comparison, etretinate was not recommended at all for women who planned to become pregnant.
Acitretin is the least toxic systemic treatment for psoriasis. It is a oral retinoid ofchoice used in the treatment of severe resistant psoriasis. It binds to nuclear receptors that regulate gene transcription. They induce keratinocyte differentiation and reduce epidermal hyperplasia. Acitretin is readily absorbed and widely distributed after oral administration. A therapeutic effect occurs after 2 to 4 weeks or longer.
|
||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
